Amanote Research
Register
Sign In
Correction: Phase 2 Study of Pembrolizumab in Patients With Advanced Rare Cancers
Journal for ImmunoTherapy of Cancer
- United Kingdom
doi 10.1136/jitc-2019-000347corr1
Full Text
Open PDF
Abstract
Available in
full text
Categories
Oncology
Molecular Medicine
Pharmacology
Cancer Research
Allergy
Immunology
Date
April 1, 2020
Authors
Unknown
Publisher
BMJ
Related search
P1.01-106 Pembrolizumab Randomized, Phase 1 Study in Chinese Patients With Advanced NSCLC: KEYNOTE-032
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Immunogenicity of Pembrolizumab in Patients With Advanced Tumors
Journal for ImmunoTherapy of Cancer
Oncology
Molecular Medicine
Pharmacology
Cancer Research
Allergy
Immunology
Phase 1 Study of Intravenous Oncolytic Poxvirus (vvDD) in Patients With Advanced Solid Cancers
Molecular Therapy
Molecular Medicine
Molecular Biology
Pharmacology
Medicine
Genetics
Drug Discovery
Phase 2 Study of Lenvatinib in Patients With Advanced Hepatocellular Carcinoma
Journal of Gastroenterology
Gastroenterology
A Phase 2 and Biomarker Study of Cabozantinib in Patients With Advanced Cholangiocarcinoma
Cancer
Cancer Research
Oncology
Randomized Phase II Study of the Bruton Tyrosine Kinase Inhibitor Acalabrutinib, Alone or With Pembrolizumab in Patients With Advanced Pancreatic Cancer
Journal for ImmunoTherapy of Cancer
Oncology
Molecular Medicine
Pharmacology
Cancer Research
Allergy
Immunology
Phase I/Ii Trial of Imatinib and Bevacizumab in Patients With Advanced Melanoma and Other Advanced Cancers
Oncologist
Cancer Research
Medicine
Oncology
Pembrolizumab Monotherapy in Patients With Primary Refractory Classical Hodgkin Lymphoma: Subgroup Analysis of the Phase 2 Keynote-087 Study
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Imatinib and Everolimus in Patients With Progressing Advanced Chordoma: A Phase 2 Clinical Study
Cancer
Cancer Research
Oncology